{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:07:10Z","timestamp":1758402430913},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1053\/j.seminoncol.2007.11.007","type":"journal-article","created":{"date-parts":[[2008,1,7]],"date-time":"2008-01-07T12:19:03Z","timestamp":1199708343000},"page":"S1-S2","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S5","title":["Introduction"],"prefix":"10.1053","volume":"34","author":[{"given":"Hagop M.","family":"Kantarjian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2007.11.007_bib2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(75)91950-9","article-title":"Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity","volume":"1","author":"Giblett","year":"1975","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2007.11.007_bib3","first-page":"45","article-title":"Purine nucleoside phosphorylase deficiency","volume":"3","author":"Markert","year":"1991","journal-title":"Immunodef Rev"},{"key":"10.1053\/j.seminoncol.2007.11.007_bib4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/00912700022008991","article-title":"Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers","volume":"40","author":"Viegas","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2007.11.007_bib5","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1567-5769(01)00056-X","article-title":"Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)\u2014A novel potent and orally active immunosuppressive agent","volume":"1","author":"Bantia","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1053\/j.seminoncol.2007.11.007_bib6","doi-asserted-by":"crossref","first-page":"8615","DOI":"10.1021\/bi980658d","article-title":"One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase","volume":"37","author":"Miles","year":"1998","journal-title":"Biochemistry"},{"key":"10.1053\/j.seminoncol.2007.11.007_bib7","first-page":"243","article-title":"Purine nucleoside phosphorylase inhibitors in T-cell malignancies","volume":"7","author":"Bantia","year":"2004","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1053\/j.seminoncol.2007.11.007_bib8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1567-5769(03)00076-6","article-title":"Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor\u2014BCX-1777","volume":"3","author":"Bantia","year":"2003","journal-title":"Int Immunopharmacol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.007_bib9","first-page":"512b","article-title":"Preliminary activity of intravenous BCX-1777 in aggressive T-cell malignancies","volume":"102","author":"Thomas","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.007_bib10","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2005-03-1309","article-title":"A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)","volume":"106","author":"Gandhi","year":"2005","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.007_bib11","first-page":"524a","article-title":"Forodesine IV (BCX-1777) is clinically active in relapsed\/refractory T-cell leukemia: Results of a phase II study (interim report)","volume":"108","author":"Furman","year":"2006","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.007_bib12","first-page":"698a","article-title":"Oral forodesine (BCX-1777) is clinically active in refractory cutaneous T-cell lymphoma: Results of a phase I\/II study","volume":"108","author":"Duvic","year":"2006","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.007_bib13","first-page":"683a","article-title":"Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma","volume":"104","author":"Duvic","year":"2004","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.007_bib14","first-page":"533a","article-title":"Phase II study of forodesine, a PNP inhibitor, in patients with relapsed or refractory B-lineage acute lymphoblastic leukemia","volume":"108","author":"Ritchie","year":"2006","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.007_bib15","first-page":"750a","article-title":"Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I\/II studies in patients with B-cell acute lymphoblastic leukemia","volume":"104","author":"Furman","year":"2004","journal-title":"Blood"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775407002266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775407002266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T22:57:23Z","timestamp":1546383443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775407002266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":14,"alternative-id":["S0093775407002266"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2007.11.007","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}